Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

Theriva Biologics Inc
Healthcare
P/NCAV
0.51x
Ticker
TOVX
Exchange
Nyse American LLC
Country
United States
Close
0.37 $
Mkt Cap
6.0M $
EV
-16.9M $
NCAV Burn Rate
57.9%
Current Ratio
4.07
Debt/Equity
0.01
EV/REV
N/Ax
EV/EBIT
0.8x
EV/FCF
0.9x
Dilution
65.0% p.A
Total Net Income
-197.0M $
Cheapness
98.0%
Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. It is advancing a new oncolytic adenovirus platform. Its candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01 is an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment. SYN-004 (ribaxamase) is designed to degrade certain commonly used intravenous beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage. SYN-020 is a recombinant oral formulation of the enzyme intestinal alkaline phosphatase produced under current good manufacturing practice conditions and intended to treat both local GI and systemic diseases. Its research programs include VCN-11 Albumin Shield Technology and SYN-006, SYN-007, other oncolytic virus.

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average